Comparative Pharmacology
Head-to-head clinical analysis: CEFIZOX IN PLASTIC CONTAINER versus FORTAZ IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFIZOX IN PLASTIC CONTAINER versus FORTAZ IN PLASTIC CONTAINER.
CEFIZOX IN PLASTIC CONTAINER vs FORTAZ IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to penicillin-binding proteins (PBPs) in bacterial cell wall, inhibiting peptidoglycan cross-linking, leading to cell lysis and death.
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP3, thereby disrupting peptidoglycan cross-linking and leading to cell lysis. It is a third-generation cephalosporin with broad-spectrum activity against Gram-negative bacteria, including Pseudomonas aeruginosa.
1-2 g IV/IM every 8-12 hours; severe infections: up to 2 g every 6-8 hours; maximum 12 g/day.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day.
None Documented
None Documented
1.5-2 hours; prolonged to 10-30 hours in severe renal impairment (CrCl <10 mL/min)
1.8 hours in normal adults; prolonged to 3-5 hours in neonates and 10-30 hours in severe renal impairment (CrCl <10 mL/min)
Primarily renal (80-90% unchanged), with biliary/fecal elimination being minor (<10%)
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; minor biliary/fecal (<10%)
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic